Fig. 1From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapyTherapy procedures (21-day cycle). Oxaliplatin:130mg/m2, ivgtt, d1; anlotinib: 12mg, po, qd, d1–14; capecitabine: 850mg/m2, po, bid, d1–14Back to article page